Qiagen N.V. (QGEN) Stock: Price, Forecast & Analyst Target
Qiagen N.V. (QGEN) — MoonshotScore 86/100 (Exceptional band), calculated Oct 5, 2026. Price $45.79 (+2.32%), as of the Oct 5, 2026 trading session; market cap $9.23B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 11.63× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Nov 3, 2026
Qiagen N.V. · QGEN · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-13: QIAGEN sells the tools that move biological material from collection and purification through molecular testing and interpretation, with consumables supplying most of its revenue. The case rests on whether its installed workflows can generate durable consumables demand while restrained sales growth, sizable debt and a shrinking cash balance leave less room for disappointment.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Qiagen (QGEN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a strong balance sheet and durable growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $535M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 6 of 8
- Altman Z 3.71 · Piotroski F 7
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 85 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional |
The score moved from 87 in the stored Oct 4, 2026 snapshot to 86 in the current publication computed Oct 5, 2026 (-1); the largest pillar moves were Growth Durability -4 and Momentum -1.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $45.79 | |
| Change on the day | +2.32% | |
| 52-week range | $32.53–$57.82 | |
| Market capitalisation | $9.23B | |
| Price / earnings (trailing) | 22.95 | |
| Shares traded on the day | 3.05M | |
| Beta (volatility vs the S&P 500) | 0.63 | |
| Dividends per share (last 12 months) | $2.64 | |
| Dividend yield (last 12 months) | 5.90% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
For the third quarter, we expect total net sales growth of about 1% to 2% CER and adjusted diluted EPS of at least $0.62 at CER.
Roland Sackers · Statement from
For the full year, we are reaffirming our outlook for total net sales growth of about 1 to 2 percentage points at CER.
Roland Sackers · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Qiagen (QGEN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 3, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the QGEN film — every key number, told as a short cinematic story
~2 min · open the film
What is Qiagen (QGEN), and what does it report?
Short answer · as of
QIAGEN is not chiefly a laboratory-instrument vendor.
Research dated 2026-09-13.
QIAGEN is not chiefly a laboratory-instrument vendor. It supplies purification kits, assay consumables, amplification products, sequencing preparation, diagnostic tests, instruments, bioinformatics and software to molecular-diagnostics and life-science customers; instruments place workflows, while recurring kit and assay use drives the larger revenue pool.
Reported revenue therefore blends demand from research laboratories and clinical testing with product categories spanning sample preparation, diagnostic solutions, genomics and nucleic-acid amplification. The consumables-heavy mix matters because testing and experiment volume can influence sales after an instrument has already been installed.
What do the latest results show for Qiagen (QGEN)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $535M.
Research dated 2026-09-13.
The latest reported period brought a rebound from the preceding period: revenue, gross profit, operating profit, net income and cash generated from operations all increased. Revenue also came in above the prevailing estimate, reversing the modest shortfall recorded in the prior report.
Across the broader annual series, sales have recovered from their trough but remain below the earlier peak, while net income has been far less stable than revenue. Management has reaffirmed modest constant-currency sales growth, framing the near-term path as gradual expansion rather than a sharp acceleration.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $535.04M Jun 30, 2026
- Latest quarter · R&D
- $50.43M Jun 30, 2026
- Latest quarter · SG&A
- $146.77M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $132.40M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $535.04M | $50.43M | $146.77M | $132.40M |
| Mar 31, 2026 | $492.32M | $48.26M | $142.39M | $116.63M |
| Dec 31, 2025 | $540.42M | $47.23M | $153.88M | $153.90M |
| Sep 30, 2025 | $532.58M | $48.75M | $143.11M | $129.16M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $535.04M Aug 5, 2026
- Latest report · revenue estimate
- $527.50M Aug 5, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 5, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 5, 2026 | $535.04M | $527.50M | $0.6200 | $0.5980 |
| May 6, 2026 | $492.32M | $496.15M | $0.5400 | $0.5420 |
| Feb 4, 2026 | $540.42M | $528.42M | $0.6200 | $0.6100 |
| Nov 4, 2025 | $532.58M | $525.91M | $0.6400 | $0.6100 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $535M | $103M | $0.50 (diluted) |
| Q1 FY2026 | $492M | $68M | $0.33 (diluted) |
| Q4 FY2025 | $540M | $108M | $0.52 (diluted) |
| Q3 FY2025 | $533M | $130M | $0.60 (diluted) |
What are the financial strengths and risks for Qiagen (QGEN)?
Short answer
Cash and short-term investments were $793.50M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $200.69M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
QIAGEN converts operations into cash consistently, and recent operating cash flow has remained comfortably above capital spending. Profitability is also substantial across gross, operating and net measures, while the quality and distress screens do not signal immediate financial strain.
The counterweight is leverage. Debt exceeds cash and investments, leaving the company in a net-debt position, and cash has declined materially across the reported window despite positive operating cash generation. The distribution pattern has also varied sharply, so recent dividend yield should not be treated as a dependable run rate without examining the underlying payments.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $200.69M Jun 30, 2026
- Previous quarter · operating cash flow
- $100.63M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $200.69M | −$42.93M |
| Mar 31, 2026 | $100.63M | −$46.88M |
| Dec 31, 2025 | $188.13M | −$70.91M |
| Sep 30, 2025 | $165.02M | −$46.04M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Qiagen (QGEN)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026.
Research dated 2026-09-13.
QIAGEN now needs to show that the latest sequential rebound can persist without sacrificing margin or cash conversion. Watch revenue against management’s modest constant-currency outlook, gross and operating profit alongside research and selling costs, and operating cash flow after capital spending.
The balance sheet deserves equal attention: stabilization in cash and short-term investments would make the leverage position less restrictive, while another material decline would raise questions about uses of cash beyond ordinary investment. Consensus expects continuing revenue and earnings growth over the forecast horizon, making execution against that gradual path more informative than any isolated estimate beat.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
For the third quarter, we expect total net sales growth of about 1% to 2% CER and adjusted diluted EPS of at least $0.62 at CER.
Roland Sackers ·
For the full year, we are reaffirming our outlook for total net sales growth of about 1 to 2 percentage points at CER.
Roland Sackers ·
What the records here don't tell us
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Qiagen compare with its peers?
Short answer
Qiagen's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
QIAGEN spans more of the molecular workflow than a focused assay maker or instrument supplier: sample stabilization and purification feed amplification, sequencing preparation, diagnostic assays and software interpretation. That breadth can deepen customer workflow exposure, but it also ties performance to a varied mix of research activity, clinical testing and consumable pull-through.
Its revenue base is dominated by consumables and related products rather than instruments alone. Investors are therefore evaluating a recurring-use model with broad workflow coverage, while current valuation measures and consensus forecasts already assume profitable, continued expansion rather than a distressed recovery.
| Company | Price | Market value | Score |
|---|---|---|---|
| $58.85 Oct 5, 2026 | $14.8B | 98 5-pillar Oct 5, 2026 | |
| $109.06 Oct 5, 2026 | $5.02B | 96 5-pillar Oct 5, 2026 | |
| $620.51 Oct 5, 2026 | $16.7B | 92 5-pillar Oct 5, 2026 | |
| Qiagen (QGEN) — this page | $45.79 | $9.23B | 86 |
| $140.65 Oct 5, 2026 | $9.98B | 83 5-pillar Oct 5, 2026 | |
| $18.55 Oct 5, 2026 | $5.29B | 77 5-pillar Oct 5, 2026 | |
| $172.89 Oct 5, 2026 | $10.1B | 75 5-pillar Oct 5, 2026 | |
| $157.36 Oct 5, 2026 | $17.6B | 71 5-pillar Oct 5, 2026 | |
| $308.65 Oct 5, 2026 | $25.3B | 71 5-pillar Oct 5, 2026 | |
| $168.33 Oct 5, 2026 | $12.9B | 70 5-pillar Oct 5, 2026 | |
| $57.54 Oct 5, 2026 | $11.1B | 65 5-pillar Oct 5, 2026 | |
| $310.77 Oct 5, 2026 | $15.0B | 62 5-pillar Oct 5, 2026 | |
| $205.00 Oct 5, 2026 | $12.8B | 36 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $38.60 – $48.00
- Consensus target
- $43.01
- Median target
- $43.00
Consensus record · Captured .
Measured against a quoted price of $45.79 (as of Oct 5, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 70.7% Period end Jun 30, 2026
- Previous quarter · ownership
- 60.0% Prior to period end Jun 30, 2026
- Reporting holders
- 364 Period end Jun 30, 2026
- Previous quarter · holders
- 377 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Wellington Management Group Llp | 12,406,763 |
| Price T Rowe Associates INC /Md/ | 11,354,379 |
| Principal Financial Group INC | 6,648,681 |
| Vanguard Capital Management LLC | 6,209,904 |
| Blackrock, INC. | 5,905,678 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Qiagen (QGEN)?
- Magnetic Beads - Global Strategic Business Report: Capitalize on the Surge from $3.3 Billion in 2025 to $7.4 Billion by 2032 as Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories and Miltenyi Biotec Battle for Leadership
- FDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance Marker
- QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
- Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51
What Investors Ask About Qiagen (QGEN) — Healthcare
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why are QIAGEN Sample Technologies important to the business?
Sample Technologies place QIAGEN at the start of molecular workflows through stabilization, purification and preparation of nucleic acids. Repeated processing of biological samples supports consumables demand before downstream amplification, sequencing or diagnostic interpretation begins.
Does QIAGEN depend mainly on selling laboratory instruments?
Consumables and related products form the dominant reported revenue category. Instruments support adoption of QIAGEN workflows, but recurring kits, assays and other consumables carry greater economic weight.
What makes QIAGEN’s QuantiFERON-style immune response testing different from its research products?
Immune-response assays serve clinical testing needs such as tuberculosis and post-transplant monitoring, while research products support gene expression, genotyping and related laboratory work. QIAGEN participates in clinical and research workflows rather than relying on a narrow testing market.
Why does QIAGEN’s cash position need watching despite strong operating cash flow?
Operations have generated cash above capital spending, yet cash and short-term investments have fallen materially across the reported window and remain below total debt. Continued cash conversion must therefore be assessed alongside leverage, distributions and other uses of liquidity.
What is the QGEN stock price today?
The last price recorded on this page for Qiagen N.V. (QGEN) is $45.79, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the QGEN price target?
The analyst consensus price target for Qiagen N.V. (QGEN) is $43.01 (range $38.60 to $48.00, median $43.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does QGEN pay a dividend?
Yes. Qiagen N.V. (QGEN) shows a trailing 12-month dividend yield of 5.90%, as of Oct 5, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (84 figures)
The 84 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Roland Sackers (Aug 6, 2026): For the third quarter, we expect total net sales growth of about 1% to 2% CER and adjusted diluted EPS of at least $0.62 at CER. Roland Sackers (Aug 6, 2026): For the full year, we are reaffirming our outlook for total net sales growth of about 1 to 2 percentage points at CER. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Hulsterweg 82, PL Venlo, 5912 PL | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Hulsterweg 82, Venlo, LI, 5912 PL, NL". |
FMP — 73 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $45.79 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:44:40.440Z. | |
px.change | Change on the day | +2.32% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $9.23B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-05. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$1.04 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $535M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $32.53–$57.82 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 22.95 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.05M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.63 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Jon Pratt | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 5,500 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $2.25B, net result $512.60M; FY2022 revenue $2.14B, net result $423.21M; FY2023 revenue $1.97B, net result $341.30M; FY2024 revenue $1.98B, net result $83.59M; FY2025 revenue $2.09B, net result $424.88M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Genomics / NGS $241.78M · Sample Technologies $661.26M · Diagnostic Solutions $803.08M · Consumables and Related $1.88B · PCR / Nucleic Acid Amplification $308.99M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 61.8% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $535.04M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $50.43M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $146.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $132.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $492.32M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $48.26M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $142.39M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $116.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $540.42M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $47.23M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $153.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $153.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $532.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $48.75M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $143.11M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $129.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-05.revenue_actual | Revenue · reported — report date 2026-08-05 | $535.04M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.revenue_estimated | Revenue · estimate — report date 2026-08-05 | $527.50M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_actual | EPS · reported — report date 2026-08-05 | $0.6200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_estimated | EPS · estimate — report date 2026-08-05 | $0.5980 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.revenue_actual | Revenue · reported — report date 2026-05-06 | $492.32M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.revenue_estimated | Revenue · estimate — report date 2026-05-06 | $496.15M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.eps_actual | EPS · reported — report date 2026-05-06 | $0.5400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.eps_estimated | EPS · estimate — report date 2026-05-06 | $0.5420 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.revenue_actual | Revenue · reported — report date 2026-02-04 | $540.42M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.revenue_estimated | Revenue · estimate — report date 2026-02-04 | $528.42M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.eps_actual | EPS · reported — report date 2026-02-04 | $0.6200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.eps_estimated | EPS · estimate — report date 2026-02-04 | $0.6100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_actual | Revenue · reported — report date 2025-11-04 | $532.58M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $525.91M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | $0.6400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | $0.6100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $793.50M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $200.69M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $17.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $1.64B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 2.75× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $200.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $100.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$42.93M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$46.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $188.13M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$70.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $165.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$46.04M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $38.60 – $48.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $43.01 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $43.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 70.7% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 60.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 364 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 377 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Wellington Management Group Llp — shares in provider snapshot | 12,406,763 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 11,354,379 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Principal Financial Group INC — shares in provider snapshot | 6,648,681 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Capital Management LLC — shares in provider snapshot | 6,209,904 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Blackrock, INC. — shares in provider snapshot | 5,905,678 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 3.71 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 11.63× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $793.50M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $2.64 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 5.90% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-05.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($535.04M) with the recorded estimate ($527.50M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-05.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.6200) with the recorded estimate ($0.5980) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 86 of 100 · Exceptional · pillars 87 / 70 / 61 / 83 / 73 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 87 (stored snapshot Oct 4, 2026) → 86 (current publication computed Oct 5, 2026) (-1) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-05. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-05.revenue_actual,earn.history.depth.2026-08-05.revenue_estimated,earn.history.depth.2026-08-05.revenue_actual.comparison,earn.history.depth.2026-08-05.eps_actual.comparison,earn.history.depth.2026-08-05.eps_actual,earn.history.depth.2026-08-05.eps_estimated,earn.history.depth.2026-05-06.revenue_actual,earn.history.depth.2026-05-06.revenue_estimated,earn.history.depth.2026-05-06.eps_actual,earn.history.depth.2026-05-06.eps_estimated,earn.history.depth.2026-02-04.revenue_actual,earn.history.depth.2026-02-04.revenue_estimated,earn.history.depth.2026-02-04.eps_actual,earn.history.depth.2026-02-04.eps_estimated,earn.history.depth.2025-11-04.revenue_actual,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Genomics / NGS: $241.78M; Sample Technologies: $661.26M; Diagnostic Solutions: $803.08M; Consumables and Related: $1.88B; PCR / Nucleic Acid Amplification: $308.99M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Cash, investments and debt | Total debt: $1.64B; Liquidity basis: cash and short-term investments; Total liabilities: $2.53B; Cash and short-term investments: $793.50M; Cash and investments: $810.50M; Long-term investments: $17.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-06 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 2836 — Biological Products, (No Diagnostic Substances). | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-05 | FMP | Financial Modeling Prep (FMP) earnings |
| Trailing twelve-month ratio set | Quick ratio: 2.31; Current ratio: 2.85; Debt to equity: 0.49; Net margin: 19.5%; Gross margin: 61.8%; Operating margin: 25.3%; Return on assets: 7%; Return on equity: 11.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 3.6; Piotroski F-score: 7 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $810.50M; Cash and short-term investments: $793.50M; Long-term investments: $17.00M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $793.50M; Decline: $686.90M; Opening balance: $1.48B; Average change per period: $98.10M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$850.10M; Total debt: $1.64B; Cash and investments: $793.50M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Recent dividends paid | Captured record · 4 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-07-07 | FMP | Financial Modeling Prep (FMP) dividend history |
| Dividends per share, last 12 months (split-adjusted) | $2.64 Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-09-13, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | 2026-07-07 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history |
| Dividend yield, last 12 months | 6.21% Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | 2026-09-11 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote |
| Next earnings report | Date: 2026-11-03; EPS estimate: $0.62 per share; Revenue estimate: $535.98M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.